Market Overview:
The global oral erectile dysfunction therapeutic market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of erectile dysfunction, rising awareness about oral therapies for treating erectile dysfunction, and growing demand for novel therapies. The protein segment is expected to dominate the global oral erectile dysfunction therapeutic market in terms of revenue during the forecast period. This segment is expected to be followed by the hormones segment. The application segments are Age 50 respectively. North America dominates this market with a share of more than 35%.
Product Definition:
Oral Erectile Dysfunction Therapeutic is a medical term used to describe the use of medications or treatments that are used to improve erectile function in men. The importance of Oral Erectile Dysfunction Therapeutic is that it can help men who are struggling with erectile dysfunction achieve and maintain an erection.
Protein:
Protein is a body constituent and an essential nutrient for the growth and repair of cells. It helps in the construction of various tissues, including skin, blood vessels, hair & nails.
Hormones:
Hormones and it’s usage in Oral Erectile Dysfunction Therapeutic market is expected to grow at a significant rate over the forecast period. The growth of this market can be attributed to factors such as rising prevalence of erectile dysfunction, increasing awareness about available treatment options, growing geriatric population base, and presence of high unmet needs in emerging economies.
Application Insights:
Based on application, the global market is segmented into age less than 20, age 20-30, and above 50 years. The above 50 years category held the largest share in 2017 owing to a high prevalence of Erectile Dysfunction (ED) in this demographic. According to a study published by NCBI in 2018, around 17% men aged 45 and above suffered from ED while 6% of them had low sexual desire or interest. Thus rising number of older population suffering from ED is expected to fuel demand for new drugs during the forecast period.
The other category includes diabetes mellitus related erectile dysfunction as well as neurologic disorders that affect erection such as Parkinson¢â‚¬â„¢s disease and spinal cord injuries.
Regional Analysis:
Europe dominated the global market in 2017. The presence of well-established healthcare infrastructure, high prevalence of chronic diseases such as diabetes and cardiovascular disorders, and availability of effective treatment for erectile dysfunction are some factors attributing to its large share. In addition, increasing awareness about various treatments available for ED is driving the demand in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising geriatric population that suffers from ED and growing number of product launches by key players operating in this space. Rising preference among patients suffering from erectile dysfunction towards herbal medicines due to their low cost may hinder market growth during the forecast period; however, technological advancements related to treatment options offered through online channels are anticipated to provide a significant boost over the next eight years thereby boosting overall revenue estimates across all regions included in our study matrix except North America where estimates were provided earlier (Table 1).
Growth Factors:
- Increasing incidence of oral erectile dysfunction
- Growing awareness about oral erectile dysfunction therapies
- Rising demand for effective and safe oral erectile dysfunction therapies
- Technological advancements in oral erectile dysfunction therapies
- Growing number of clinical studies on oral erectile dysfunction therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Erectile Dysfunction Therapeutic Market Research Report
By Type
Protein, Hormones, Other
By Application
Age <20, Age 20-30, Age 31-40, Age 41-50, Age >50
By Companies
Eli Lilly, Pfizer, Bayer, Teva Pharma, S.K. Chemicals, Seoul Pharma, CSBIO.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Oral Erectile Dysfunction Therapeutic Market Report Segments:
The global Oral Erectile Dysfunction Therapeutic market is segmented on the basis of:
Types
Protein, Hormones, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Age <20, Age 20-30, Age 31-40, Age 41-50, Age >50
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Pfizer
- Bayer
- Teva Pharma
- S.K. Chemicals
- Seoul Pharma
- CSBIO.
Highlights of The Oral Erectile Dysfunction Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protein
- Hormones
- Other
- By Application:
- Age <20
- Age 20-30
- Age 31-40
- Age 41-50
- Age >50
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Erectile Dysfunction Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral erectile dysfunction (ED) is a condition in which men have difficulty getting and maintaining an erection. ED can be caused by a variety of factors, including age, health problems, medications, and lifestyle choices. Some people may also experience occasional difficulties with sexual arousal or orgasm. Oral erectile dysfunction therapies include prescription drugs, natural remedies, and surgery.
Some of the major players in the oral erectile dysfunction therapeutic market are Eli Lilly, Pfizer, Bayer, Teva Pharma, S.K. Chemicals, Seoul Pharma, CSBIO..
The oral erectile dysfunction therapeutic market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Erectile Dysfunction Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Erectile Dysfunction Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Erectile Dysfunction Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Erectile Dysfunction Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Erectile Dysfunction Therapeutic Market Size & Forecast, 2020-2028
4.5.1 Oral Erectile Dysfunction Therapeutic Market Size and Y-o-Y Growth
4.5.2 Oral Erectile Dysfunction Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Protein
5.2.2 Hormones
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Age <20
6.2.2 Age 20-30
6.2.3 Age 31-40
6.2.4 Age 41-50
6.2.5 Age >50
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Erectile Dysfunction Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Erectile Dysfunction Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Protein
9.6.2 Hormones
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Age <20
9.10.2 Age 20-30
9.10.3 Age 31-40
9.10.4 Age 41-50
9.10.5 Age >50
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Protein
10.6.2 Hormones
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Age <20
10.10.2 Age 20-30
10.10.3 Age 31-40
10.10.4 Age 41-50
10.10.5 Age >50
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Protein
11.6.2 Hormones
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Age <20
11.10.2 Age 20-30
11.10.3 Age 31-40
11.10.4 Age 41-50
11.10.5 Age >50
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Protein
12.6.2 Hormones
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Age <20
12.10.2 Age 20-30
12.10.3 Age 31-40
12.10.4 Age 41-50
12.10.5 Age >50
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Protein
13.6.2 Hormones
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Age <20
13.10.2 Age 20-30
13.10.3 Age 31-40
13.10.4 Age 41-50
13.10.5 Age >50
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Erectile Dysfunction Therapeutic Market: Competitive Dashboard
14.2 Global Oral Erectile Dysfunction Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Pfizer
14.3.3 Bayer
14.3.4 Teva Pharma
14.3.5 S.K. Chemicals
14.3.6 Seoul Pharma
14.3.7 CSBIO.
